 |
|
| Venture Capital Bio Life Sciences (page 2 of 20) |
|
-Aperion-
Offices: Framingham, Massachusetts
Apeiron Partners is a boutique investment bank focused exclusively on the
life sciences. Apeiron is their new corporate brand replacing CPP Advisors,
which many of you already know. With a new set of exciting transaction mandates,
the changing market environment and the publication of their first book,
they too felt the need for change.
Offices: San Francisco, California
Aphelion Capital makes public and private investments in the medical technology
industry. They leverage its substantial medical technology knowledge and
deep networks to enhance returns for both the fund and the entrepreneurs
in whom the fund invests. The fund is generally a long term investor in
companies that they believe have superior products and strong management
teams. Aphelion prefers private investments where they can partner with
the company to enhance success and value appreciation.
Offices: Kalamazoo, Michigan
Apjohn Group is an accomplished team of experienced business and pharmaceutical
professionals that has demonstrated success in working with innovators to
launch life science companies. Their focus is on early stage life science
opportunities, with unique strength in biopharmaceuticals. The fourteen
partners in Apjohn Group have broad and deep expertise, as well extensive
networks, in all phases of the drug development process, from discovery
through commercialization.
Offices: London, England
Apposite extensive entrepreneurial, private equity and investment banking
skills, all focussed on healthcare, allow us to add value to companies throughout
their investment period. They have built an extensive network of relationships
across the world, including with many prestigious advisers and institutions.
This network, combined with the unrivalled reach into Japan that comes from
their backing by major Japanese corporates, allows them to provide their
companies with invaluable introductions and insights on a global basis.-Aravis-
Offices: Zurich, Switzerland
Aravis is an investment organization providing venture capital to highly
promising seed and early-stage as well as spin-off biotechnology companies
developing break-through technologies or new therapeutics. Aravis offers
its portfolio companies a unique international network that combines decades
of experience in science, operations and venture financing. Aravis’ worldwide
network within their partners opens doors in a number of geographic locations.
Offices: Ann Arbor, Michigan
Arboretum Ventures is a venture capital firm targeting investments in early-stage
life sciences companies. Their areas of focus include: medical devices and
diagnostics; pharmaceuticals and biotechnology; and, health care services.
Arboretum makes seed and early-stage investments, often representing the
founder’s first professional investor. As such, Arboretum’s principals remain
actively involved with the portfolio companies, working directly with company
founders to help establish business models.
Offices: St Louis, Missouri
A strategic healthcare venture fund focused on the medical device, technology
and service sectors. Established within Ascension Health, to invest in the
future of its 400 year legacy, AHV’s role is to construct and manage a strategic
portfolio of investments that deliver a venture investment return, have
the potential to transform the healthcare industry and significantly enhance
the quality of patient care.
Offices: Los Altos, California
Investment in emerging biotechnology companies, Astellas Venture Management
is the corporate venture capital arm of Astellas Pharma, a global pharmaceutical
company originated in Japan. The venture capital activity of Astella can
trace back to Astellas Venture Capital (originally founded as Yamanouchi
VentureCapital n 2000) and Fujisawa Investments for Entrepreneurship established
in 1999. Astella Venture Management is currently managing four funds.
Offices: Cambs, England
Avlar was founded in 1999 and manages Avlar Fund I (£21m) and Avlar Fund
II (£43m). Avlar has invested in eighteen companies across a range of sub-sectors
of the bioscience industries. Prior to the formation of Avlar Messrs Roach
and Goodman co-founded or seed financed nine life science companies. Seven
of these were listed on recognized Stock Exchanges producing highly profitable
realizations. These included Acambis, Chiroscience, Core, Salix and Oxford
Biomedica.
Print
(page 3)
Resources
to
top